Researchers are rapidly examining retatrutide, a innovative drug created by Eli Lilly, as a possible step in body management. Distinct from many existing approaches, retatrutide is a double -action receptor targeting equally GLP-1 and GIP, chemicals that impact appetite and blood sugar control .